Seattle Genetics Submits Arbitration Demand vs Daiichi Sankyo

Seattle Genetics submits demand to American Arbitration Association in dispute over ownership of technology Daiichi Sankyo uses in drug candidates.

• Says it acted after Daiichi Sankyo last week filed a declaratory judgment action in federal court in Delaware
• Says it submitted demand to put the dispute into arbitration in Seattle, “where it belongs under the agreement”
• NOTE: Nov. 5, Daiichi Sankyo Files Action on Seattle Genetics IP Claim

To contact the reporter on this story:
Jim Silver in New York at jsilver@bloomberg.net

To contact the editor responsible for this story:
Sebastian Tong at stong41@bloomberg.net

© 2019 Bloomberg L.P. All ...